WuXi XDC Cayman Inc (2268.HK)

Healthcare | Medical Diagnostics Research
Income Statement (Quarterly) 2026-04-07 2025-06-30 2025-03-31 2024-06-30
Revenue 2,700,869,000 2,700,869,000 1,350,434,500 832,599,500
Cost of Revenue 1,725,622,000 1,725,622,000 862,811,000 564,934,000
Gross Profit 975,247,000 975,247,000 487,623,500 267,665,500
Operating Expenses
R&D Expenses 0 0 0 0
SG&A Expenses 158,835,000 158,835,000 79,417,500 51,312,000
Operating Expenses 208,318,000 208,318,000 104,159,000 75,109,000
Operating Income 766,929,000 766,929,000 383,464,500 192,556,500
Interest Expense 0 0 0 0
Income Before Tax 867,150,000 867,150,000 433,575,000 280,858,000
Income Tax Expense 121,449,000 121,449,000 60,724,500 36,744,000
Net Income 745,701,000 745,701,000 372,850,500 244,114,000
Per Share
EPS 0.62 0.62 0.31 0.19
EPS Diluted 0.00 0.00 0.00 0.00
Income Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Revenue 4,052,320,000 2,123,839,000 990,423,000
Cost of Revenue 2,812,474,000 1,564,281,000 729,340,000
Gross Profit 1,239,846,000 559,558,000 261,083,000
Operating Expenses
R&D Expenses 0 0 0
SG&A Expenses 220,318,000 117,193,000 57,979,000
Operating Expenses 291,311,000 194,060,000 76,042,000
Operating Income 948,535,000 365,498,000 242,086,000
Interest Expense 3,205,000 742,000 2,916,000
Income Before Tax 1,219,791,000 359,612,000 195,801,000
Income Tax Expense 150,169,000 76,074,000 40,070,000
Net Income 1,069,622,000 283,538,000 155,731,000
Per Share
EPS 0.97 0.26 0.13
EPS Diluted 0.00 0.00 0.00
Balance Sheet (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 1,925,149,000 4,047,583,000 334,972,000
Short Term Investments 2,048,158,000 0 400,000,000
Net Receivables 1,685,714,000 874,910,000 0
Inventory 118,699,000 46,804,000 62,934,000
Total Current Assets 6,101,495,000 5,199,980,000 1,402,331,000
Property Plant Equipment 2,741,797,000 1,248,379,000 803,855,000
Goodwill and Intangibles 259,937,000 268,139,000 265,841,000
Total Assets 9,124,131,000 6,735,321,000 2,496,379,000
Liabilities
Account Payables 1,020,025,000 620,451,000 480,832,000
Short Term Debt 481,275,000 1,247,000 75,557,000
Total Current Liabilities 2,466,492,000 1,279,410,000 1,013,973,000
Long Term Debt 15,150,000 1,595,000 1,627,000
Total Liabilities 2,484,642,000 1,281,005,000 1,015,600,000
Shareholders Equity
Retained Earnings 1,432,970,000 465,604,000 169,199,000
Total Shareholders Equity 6,639,489,000 5,454,316,000 1,480,779,000
Balance Sheet (Annual) 2024-12-31 2023-12-31 2022-12-31
Assets
Cash and Cash Equivalents 1,925,149,000 4,047,583,000 334,972,000
Short Term Investments 2,048,158,000 0 400,000,000
Net Receivables 1,685,714,000 874,910,000 0
Inventory 118,699,000 46,804,000 62,934,000
Total Current Assets 6,101,495,000 5,199,980,000 1,402,331,000
Property Plant Equipment 2,741,797,000 1,248,379,000 803,855,000
Goodwill and Intangibles 259,937,000 268,139,000 265,841,000
Total Assets 9,124,131,000 6,735,321,000 2,496,379,000
Liabilities
Account Payables 1,020,025,000 620,451,000 480,832,000
Short Term Debt 481,275,000 1,247,000 75,557,000
Total Current Liabilities 2,466,492,000 1,279,410,000 1,013,973,000
Long Term Debt 15,150,000 1,595,000 1,627,000
Total Liabilities 2,484,642,000 1,281,005,000 1,015,600,000
Shareholders Equity
Retained Earnings 1,432,970,000 465,604,000 169,199,000
Total Shareholders Equity 6,639,489,000 5,454,316,000 1,480,779,000
Cash Flow Statement (Quarterly) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income 1,219,791,000 359,612,000 195,801,000
Depreciation & Amortization 110,388,000 59,513,000 30,812,000
Stock Based Compensation 104,383,000 75,153,000 38,626,000
Change in Working Capital -400,679,000 -94,415,000 -5,991,000
Operating Cash Flow 717,223,000 332,845,000 251,816,000
Investing Activities
Capital Expenditure -1,505,176,000 -539,360,000 -387,556,000
Investments -1,505,176,000 -529,360,000 -387,556,000
Investing Cash Flow -3,330,455,000 -91,233,000 -1,279,543,000
Financing Activities
Debt Repayment 478,000,000 -71,144,000 -88,454,000
Common Stock Issued/Repurchased 3,637,000 3,603,962,000 1,285,462,000
Dividends Paid 0 0 0
Financing Cash Flow 475,360,000 3,522,104,000 1,328,213,000
Summary
Free Cash Flow -787,953,000 -206,515,000 -135,740,000
Net Change in Cash -2,122,434,000 3,712,611,000 308,647,000
Cash Flow Statement (Annual) 2024-12-31 2023-12-31 2022-12-31
Operating Activities
Net Income 1,219,791,000 359,612,000 195,801,000
Depreciation & Amortization 110,388,000 59,513,000 30,812,000
Stock Based Compensation 104,383,000 75,153,000 38,626,000
Change in Working Capital -400,679,000 -94,415,000 -5,991,000
Operating Cash Flow 717,223,000 332,845,000 251,816,000
Investing Activities
Capital Expenditure -1,505,176,000 -539,360,000 -387,556,000
Investments -1,505,176,000 -529,360,000 -387,556,000
Investing Cash Flow -3,330,455,000 -91,233,000 -1,279,543,000
Financing Activities
Debt Repayment 478,000,000 -71,144,000 -88,454,000
Common Stock Issued/Repurchased 3,637,000 3,603,962,000 1,285,462,000
Dividends Paid 0 0 0
Financing Cash Flow 475,360,000 3,522,104,000 1,328,213,000
Summary
Free Cash Flow -787,953,000 -206,515,000 -135,740,000
Net Change in Cash -2,122,434,000 3,712,611,000 308,647,000